A phase i study of lapatinib with whole brain radiotherapy in patients with Human Epidermal Growth Factor Receptor 2 (HER2)-positive breast cancer brain metastases

Breast Cancer Research and Treatment

Volumn 142, Issue 2, 2013, Pages 405-414

  Lin, Nancy U ^a   Freedman, Rachel A ^a   Ramakrishna, Naren ^b   Younger, Jerry ^c   Storniolo, Anna Maria ^d   Bellon, Jennifer R ^e   Come, Steven E ^f   Gelman, Rebecca S ^a   Harris, Gordon J ^g   Henderson, Mark A ^d   MacDonald, Shannon M ^c   Mahadevan, Anand ^f   Eisenberg, Emily ^a   Ligibel, Jennifer A ^a   Mayer, Erica L ^a   Moy, Beverly ^c   Eichler, April F ^c   Winer, Eric P ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b M D ANDERSON CANCER CENTER ORLANDO   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^d INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

^f BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^g MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Brain metastases; Breast cancer; Lapatinib; Whole brain radiotherapy

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; TRASTUZUMAB;

ABDOMINAL PAIN; ACNE; ADULT; AGED; ALOPECIA; ANOREXIA; ARTHRALGIA; ARTICLE; BACKACHE; BLOOD TOXICITY; BRAIN METASTASIS; BRAIN RADIATION; BREAST CANCER; CENTRAL NERVOUS SYSTEM DISEASE; CHEILITIS; CLINICAL ARTICLE; COHORT ANALYSIS; CONSTIPATION; CONTROLLED STUDY; COUGHING; DEHYDRATION; DEPRESSION; DIARRHEA; DIZZINESS; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; DRY SKIN; DYSPEPSIA; EYE DISEASE; FATIGUE; FEASIBILITY STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPERGLYCEMIA; HYPERKALEMIA; HYPERTENSION; HYPOALBUMINEMIA; HYPOCALCEMIA; HYPOKALEMIA; HYPONATREMIA; HYPOTENSION; HYPOXIA; IMMUNOHISTOCHEMISTRY; INFECTION; INSOMNIA; LIMB PAIN; LOADING DRUG DOSE; LUNG DISEASE; LUNG EMBOLISM; MALE; MAXIMUM TOLERATED DOSE; MEMORY DISORDER; MOTOR NEUROPATHY; MUCOSA INFLAMMATION; MUSCULOSKELETAL PAIN; NAUSEA; NEUROTOXICITY; OUTCOME ASSESSMENT; PAIN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEINURIA; PRURITUS; QUALITY OF LIFE; RADIATION DERMATITIS; RADIATION DOSE FRACTIONATION; RASH; RESPIRATORY TRACT DISEASE; SEIZURE; SENSORY NEUROPATHY; THROMBOSIS; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT DISEASE; VOMITING; WEAKNESS;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; BREAST NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; QUALITY OF LIFE; QUINAZOLINES; RECEPTOR, ERBB-2; TREATMENT OUTCOME;

EID: 84890439476     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-013-2754-0     Document Type: Article

References (31)

1. Bendell JC, Domchek SM, Burstein HJ, Harris L, Younger J, Kuter I, Bunnell C, Rue M, Gelman R, Winer E (2003) Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer 97:2972-2977
2. Clayton AJ, Danson S, Jolly S, Ryder WD, Burt PA, Stewart AL, Wilkinson PM, Welch RS, Magee B, Wilson G et al (2004) Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer. Br J Cancer 91:639-643
3. Pestalozzi BC, Holmes E, de Azambuja E, Metzger-Filho O, Hogge L, Scullion M, Lang I, Wardley A, Lichinitser M, Sanchez RI et al (2013) CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1-01). Lancet Oncol 14:244-248
4. Gori S, Rimondini S, De Angelis V, Colozza M, Bisagni G, Moretti G, Sidoni A, Basurto C, Aristei C, Anastasi P et al (2007) Central nervous system metastases in HER-2 positive metastatic breast cancer patients treated with trastuzumab: incidence, survival, and risk factors. Oncologist 12:766-773
5. Eichler AF, Kuter I, Ryan P, Schapira L, Younger J, Henson JW (2008) Survival in patients with brain metastases from breast cancer: the importance of HER-2 status. Cancer 112:2359-2367
6. Sperduto PW, Kased N, Roberge D, Xu Z, Shanley R, Luo X, Sneed PK, Chao ST, Weil RJ, Suh J et al (2012) Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. J Clin Oncol 30:419-425
7. Xia W, Mullin RJ, Keith BR, Liu LH, Ma H, Rusnak DW, Owens G, Alligood KJ, Spector NL (2002) Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways. Oncogene 21:6255-6263
8. Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, Jagiello-Gruszfeld A, Crown J, Chan A, Kaufman B et al (2006) Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355:2733-2743
9. Blackwell KL, Burstein HJ, Storniolo AM, Rugo H, Sledge G, Koehler M, Ellis C, Casey M, Vukelja S, Bischoff J et al (2010) Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, Trastuzumab-refractory metastatic breast cancer. J Clin Oncol 28:1124-1130
10. Palmieri D, Bronder JL, Herring JM, Yoneda T, Weil RJ, Stark AM, Kurek R, Vega-Valle E, Feigenbaum L, Halverson D et al (2007) Her-2 overexpression increases the metastatic outgrowth of breast cancer cells in the brain. Cancer Res 67:4190-4198
11. Gril B, Palmieri D, Bronder JL, Herring JM, Vega-Valle E, Feigenbaum L, Liewehr DJ, Steinberg SM, Merino MJ, Rubin SD et al (2008) Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain. J Natl Cancer Inst 100:1092-1103
12. Kuhn JG, Robbins H, Mehta M, Fine HA, Cloughesy T, Wen PY, Chang S, DeAngelis L, Lieberman F, Reardon D et al (2008) Tumor Sequestration of Lapatinib (NABTC 04-01). Neuro Oncol 10:783 (Abstract ET-05)
13. Morikawa A, Peereboom D, Smith QR, Thorsheim HR, Lockman PR, Simmons J, Weil RJ, Tabar V, Steeg PS, Seidman A (2013) Clinical evidence for drug penetration of capecitabine and lapatinib uptake in resected brain metastases from women with metastatic breast cancer. Presented at the 2013 American Society of Clinical Oncology Meeting (Chicago, IL). J Clin Oncol 31 (suppl; abstr 514)
14. Lin NU, Carey LA, Liu MC, Younger J, Come SE, Ewend M, Harris GJ, Bullitt E, Van den Abbeele AD, Henson JW et al (2008) Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 26:1993-1999
15. Zhou H, Kim YS, Peletier A, McCall W, Earp HS, Sartor CI (2004) Effects of the EGFR/HER2 kinase inhibitor GW572016 on EGFR- and HER2-overexpressing breast cancer cell line proliferation, radiosensitization, and resistance. Int J Radiat Oncol Biol Phys 58:344-352
16. Sartor CI (2004) Mechanisms of disease: radiosensitization by epidermal growth factor receptor inhibitors. Nat Clin Pract Oncol 1:80-87
17. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassem J et al (2006) Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354:567-578
18. Storniolo AM, Pegram MD, Overmoyer B, Silverman P, Peacock NW, Jones SF, Loftiss J, Arya N, Koch KM, Paul E et al (2008) Phase I dose escalation and pharmacokinetic study of lapatinib in combination with trastuzumab in patients with advanced ErbB2-positive breast cancer. J Clin Oncol 26:3317-3323
19. Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, Langer C, Murphy B, Cumberlin R, Coleman CN et al (2003) CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 13:176-181
20. Cockrell JR, Folstein MF (1988) Mini-Mental State Examination (MMSE). Psychopharmacol Bull 24:689-692
21. Folstein MF, Robins LN, Helzer JE (1983) The mini-mental state examination. Arch Gen Psychiatry 40:812
22. Weitzner MA, Meyers CA, Gelke CK, Byrne KS, Cella DF, Levin VA (1995) The Functional Assessment of Cancer Therapy (FACT) scale. Development of a brain subscale and revalidation of the general version (FACT-G) in patients with primary brain tumors. Cancer 75:1151-1161
23. Osoba D, Aaronson NK, Muller M, Sneeuw K, Hsu MA, Yung WK, Brada M, Newlands E (1996) The development and psychometric validation of a brain cancer quality-of-life questionnaire for use in combination with general cancer-specific questionnaires. Qual Life Res 5:139-150
24. Folstein MF, Folstein SE, McHugh PR (1975) "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189-198
25. Tsao MN, Lloyd N, Wong RK, Chow E, Rakovitch E, Laperriere N, Xu W, Sahgal A (2012) Whole brain radiotherapy for the treatment of newly diagnosed multiple brain metastases. Cochrane Database Syst Rev 4:CD003869
26. Tsao M, Xu W, Sahgal A (2012) A meta-analysis evaluating stereotactic radiosurgery, whole-brain radiotherapy, or both for patients presenting with a limited number of brain metastases. Cancer 118:2486-2493
27. Viani GA, Manta GB, Fonseca EC, De Fendi LI, Afonso SL, Stefano EJ (2009) Whole brain radiotherapy with radiosensitizer for brain metastases. J Exp Clin Cancer Res 28:1
28. Suh J, et al. (2008) Results of the Phase III ENRICH (RT-016) study of efaproxiral administered concurrent with whole brain radiation therapy (WBRT) in women with brain metastases from breast cancer. Int J Radiat Oncol Biol Phys 72(1 Suppl): Abstract 110
29. Bachelot T, Romieu G, Campone M, Dieras V, Cropet C, Dalenc F, Jimenez M, Le Rhun E, Pierga JY, Goncalves A et al (2013) Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study. Lancet Oncol 14:64-71
30. Chargari C, Kirova YM, Dieras V, Castro Pena P, Campana F, Cottu PH, Pierga J, Fourquet A (2009) Concurrent capecitabine and whole-brain radiotherapy for treatment of brain metastases in breast cancer patients. J Neurooncol 93:379-384
31. Olson R, Tyldesley S, Carolan H, Parkinson M, Chhanabhai T, McKenzie M (2011) Prospective comparison of the prognostic utility of the Mini Mental State Examination and the Montreal Cognitive Assessment in patients with brain metastases. Support Care Cancer 19:1849-1855